<DOC>
	<DOCNO>NCT02928211</DOCNO>
	<brief_summary>Single center , open-label study cohort define accord number administration medical imaging agent , Aftobetin-HCl receive . The medical imaging agent ( ointment ) apply cornea time detection optimal fluorescence ( amyloid burden ) lens eye determine . This measure Sapphire II device subject cognitively normal , mild cognitive impairment mild Alzheimer 's Disease .</brief_summary>
	<brief_title>Aftobetin-HCl Fluorescence Detection Measured Sapphire II Determine Number Timing Administrations</brief_title>
	<detailed_description>A single center , open label study . 35-50 subject enrol . Subjects undergo follow procedure : - Complete physical neurologic examination ( Screening ) - Neuropsychological testing ( Screening ) - Ophthalmologic examination ( Screening Visit 3 - Safety follow visit ) - Administration ointment - 1 2 administration ( Visit 1 ) - Sapphire II Fluorescent Eye Measurements ( Visit 1 &amp; 2 ) : 1 , 2 , 3 , 4 , 5 , 6 hour ( +/-10 minute ) 24 hour ( +/- 2 hour ) last ointment administration - Amyvid Positron Emission Tomography ( PET ) Amyloid Scan ( Screening cognitively normal subject Visit 4 MCI mild AD subject ) Subjects also ask participate elective second Sapphire II assessment ass reproducibility . Repeatability test optional require separate consent . Subject come back Visit 5 ( ointment administration eye scan ) , Visit 6 ( 24 hour scan ) , Visit 7 ( follow safety assessment ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>For MCI mild AD subject : 1 . Aged 5590 year old inclusive ; 2 . Able provide inform consent ; 3 . Subject must report memory concern verify study partner ; 4 . Capable cooperate duration study procedures assessment ; 5 . Magnetic Resonance Imaging ( MRI ) Scan within 6 month : Modified Hachinski Score less 4 No evidence infection , infarction ( ischemic hemorrhagic ) , focal lesion ( tumor , subdural hematoma , malformation , etc . ) 6 . Geriatric Depression Scale ( GDS ) score less 6 ; 7 . Neuropsychiatric Inventory ( NPI ) total score less 10 less 4 NPI domain ; 8 . Sufficient vision least one eye hearing participate cognitive testing ; For MCI subject : 9 . Meets National Institute AgingAlzheimer 's Association ( NIAAA ) core clinical criterion Mild Cognitive Impairment due AD ; 10 . Clinical dementia Rating Scale Score ( CDR ) 0.5 ( memory box score must = 0.5 ) ; 11 . MiniMental State Exam ( MMSE ) score less 24 ; 12 . Abnormal memory function education adjust Wechsler Memory Scale Logical Memory II subscale ( Delayed Paragraph Recall , Paragraph A ) Revised ( 16 year : less 11 ; 815 year : less 9 ; 07 year : less 6 ) ; 13 . Absence dementia : significant impairment cognitive functioning Activities Daily Living ( AODLs ) Functional Assessment Questionnaire ( FAQ ) score less 6 . The FAQ answer study partner ; For Mild AD subject : 14 . Meets National Institute AgingAlzheimer 's Association ( NIAAA ) core clinical criterion probable AD dementia ; 15 . CDR 0.5 1 ; 16 . MMSE score 20 26 ( inclusive ) ; 17 . Abnormal memory function education adjust Wechsler Memory Scale Logical Memory II subscale ( Delayed Paragraph Recall , Paragraph A ) Revised ( 16 year : less 8 ; 815 year : less 4 ; 07 year : less 2 ) ; 18 . Functional Assessment Questionaire ( FAQ ) score great 6 . The FAQ answer study partner ; For CN subject : 19 . Subject must free memory complaint ; 20 . Cognitively normal , base absence significant impairment cognitive function activity daily live ; 21 . Normal memory function document score education adjust cutoff Logical Memory II subscale ( Delayed Paragraph Recall , Paragraph A ) Wechsler Memory Scale Revised ( great equal 11 16 year education ; great equal 9 815 year education ; 22 . MMSE score 2930 ; 23 . CDR Scale Score 0 ; 24 . Aged 2150 year old inclusive ; 25 . Normal PET Amyvid Scan ( perform study criterion meet ) 1 . Serious underlie medical disease opinion investigator may interfere participant 's ability participate study unstable cardiac , pulmonary , renal , hepatic , endocrine , hematologic , active malignancy infectious disease ; 2 . NonAD cause dementia could cause impaired memory rule standardized work dementia ; 3 . Significant neurologic disease ( e.g. , Parkinson 's Disease , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis ) ; 4 . Clinically relevant abnormal serum chemistry , B12 , TSH , CBC le 6 month study entry ; 5 . History significant head trauma follow persistent neurologic default know structural brain abnormality , learn disability mental retardation ; 6 . Significant psychiatric illness last year major depression , bipolar , obsessive compulsive psychotic disorder ; 7 . History alcohol substance abuse last year ; 8 . Pain sleep disorder could interfere cognitive testing ; 9 . Known hypersensitivity Amyvid ( FlorbetapirF 18 ) component injection formulation contraindication PET scan ( e.g. , pregnant , lactating , childbearing potential ) ; 10 . Receiving investigational medication participate trial investigational medication within 30 day prior study entry ; 11 . History bilateral cataract surgery ; 12 . Active ocular inflammation infection ; 13 . History physical injury serious eye disease ; 14 . Corneal disease prevents visualization lens , e.g , Fuch 's dystrophy keratokonus ; 15 . Unable tolerate PET environment , e.g. , due physical size and/or claustrophobia ; 16 . Serious suicidal ideation opinion investigator answer 'yes ' Item 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) screening ; 17 . Inability undergo MRI procedure ( e.g. , metal implant , metallic device , e.g. , nonMRIsafe cardiac pacemaker neurostimulator , artificial joint , metal pin , surgical clip , implant metal , claustrophobia discomfort confine space ) ; 18 . May take follow psychoactive medication : Regular use narcotic analgesic ( great 2 dos week ) , Clonidine , neuroleptic , antidepressant central anticholinergic activity , Other agent central anticholinergic activity diphenhydramine , hydroxyzine , benztropine , Diazepam , clonazepam , temazepam , chlordiazepoxide , triazolam Note : permit remain following psychoactive medication provide subject receive great 4 week : Antidepressants lack significant anticholinergic side effect Estrogen replacement therapy Gingko biloba Sedative hypnotic : lorazepam , buspirone , oxazepam , zolpidem , zaleplon , alprazolam , chloral hydrate Note : permit remain following psychoactive medication provide subject receive great 12 week : Cholinesterase inhibitor Memantine Note : washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic ) must least 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>